This article is more than 5 years old. Information may no longer be current.

NovaBay net loss increases in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals reported a second quarter net loss of $2.5 million, or $0.14 per share, compared with a net loss of $1.6 million, or $0.09 per share, in the same period of 2018, according to a press release.

Net sales in the second quarter totaled $1.8 million compared with $2.8 million a year ago; $1.6 million came from sales of Avenova and $0.2 million from a stocking order.

Sales and marketing expenses were $1.5 million in second quarter 2019 compared with $3 million during the same period in 2018. Research and development expenses decreased from $61,000 to $32,000, and general and administrative expenses decreased from $1.4 million to $1.2 million.

NovaBay had cash and cash equivalents of $3.7 million as of June 30.